WIJNBERG SANDRA S 4

What Happened

• Sandra S. Wijnberg, a Cognizant (CTSH) director, was granted a total of 140.219 equity units on Feb 26, 2026 via awards (code A). The grants comprise 23.355 deferred stock units, 102.2 restricted stock units, and 14.664 restricted stock units. All were reported at $0.00 per unit (no cash paid); these are derivative awards representing rights to receive one share of Class A common stock per unit upon settlement.

Key Details

• Transaction date: 2026-02-26; Form 4 filed: 2026-03-02 (reporting period 2026-02-26).
• Price: $0.00 per unit; total reported cash value = $0.
• Units granted: 23.355 deferred stock units; 102.2 restricted stock units; 14.664 restricted stock units — total 140.219 units.
• Vesting/settlement notes:
  • The 23.355 units reflect dividend equivalents on deferred stock units; they are fully vested and Wijnberg elected to defer settlement until a trigger event (change in control, death/permanent disability, or the first July 1 after termination) per the Non‑Employee Director Compensation Guidelines.
  • The 102.2 units reflect dividend equivalents on previously outstanding restricted stock units and are fully vested; Wijnberg also elected deferred settlement under the same guidelines.
  • The 14.664 units are restricted stock units representing contingent rights; they will vest fully on June 3, 2026, and Wijnberg has elected deferred settlement subject to the same triggers.
• Shares owned after the transaction: not specified in the provided summary — see the full Form 4 for post-transaction holdings.
• Filing timeliness: Form 4 was filed on Mar 2, 2026 for a Feb 26, 2026 transaction; filing appears to be within the standard reporting window (not marked late).

Context

• These transactions are awards/grants (not open-market purchases or sales). Deferred stock units (DSUs) and restricted stock units (RSUs) are common elements of non-employee director compensation and represent the right to receive shares in the future rather than immediate purchases or sales. Because settlement is deferred and no cash was exchanged, these grants are routine compensation and should be interpreted as non-sale insider activity rather than an immediate bullish purchase.